X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (41) 41
animals (28) 28
index medicus (28) 28
oncology (23) 23
mice (21) 21
mice, scid (15) 15
hematology (14) 14
mice, inbred nod (13) 13
adoptive immunotherapy (12) 12
biotechnology & applied microbiology (12) 12
medicine, research & experimental (12) 12
cell line, tumor (11) 11
female (11) 11
in-vitro (11) 11
self-renewal (11) 11
antitumor-activity (9) 9
cik cells (9) 9
cancer (8) 8
cytokine-induced killer cells - immunology (8) 8
hematopoietic stem cells - cytology (8) 8
immunotherapy (8) 8
cytokine-induced killer cells - transplantation (7) 7
flow cytometry (7) 7
immunophenotyping (7) 7
male (7) 7
solid tumors (7) 7
therapy (7) 7
transplantation (7) 7
acute myeloid-leukemia (6) 6
expansion (6) 6
expression (6) 6
fetal blood - cytology (6) 6
gene expression regulation, neoplastic - drug effects (6) 6
hematopoietic stem cells (6) 6
immunotherapy, adoptive (6) 6
melanoma - immunology (6) 6
osteosarcoma (6) 6
transplantation, heterologous (6) 6
xenograft model antitumor assays (6) 6
apoptosis (5) 5
apoptosis - drug effects (5) 5
cd8 t-cells (5) 5
cell biology (5) 5
cell division - drug effects (5) 5
cell proliferation (5) 5
cells, cultured (5) 5
chemotherapy (5) 5
cord blood (5) 5
cytokines - pharmacology (5) 5
genetic vectors (5) 5
graft survival (5) 5
human hematopoietic-cells (5) 5
immunology (5) 5
immunotherapy, adoptive - methods (5) 5
induced killer-cells (5) 5
melanoma (5) 5
melanoma - therapy (5) 5
neoplasms - therapy (5) 5
research (5) 5
stem-cells (5) 5
amplification (4) 4
anticancer properties (4) 4
antigens, cd34 (4) 4
antigens, neoplasm - immunology (4) 4
antineoplastic agents - pharmacology (4) 4
antitumor activity (4) 4
biochemistry & molecular biology (4) 4
bone-marrow (4) 4
cell culture techniques - methods (4) 4
cell proliferation - drug effects (4) 4
drug therapy (4) 4
engraftment (4) 4
ex-vivo expansion (4) 4
immune-deficient mice (4) 4
interleukin-3 - pharmacology (4) 4
lymphocytes (4) 4
melanoma - drug therapy (4) 4
middle aged (4) 4
neoplasms - immunology (4) 4
niacinamide - analogs & derivatives (4) 4
phase-i (4) 4
phase-ii (4) 4
progenitor cells (4) 4
t-cells (4) 4
tumors (4) 4
activation (3) 3
adult (3) 3
aged (3) 3
animal models (3) 3
antineoplastic agents - therapeutic use (3) 3
breast cancer (3) 3
cancer research (3) 3
cancer stem cells (3) 3
cell culture techniques (3) 3
cell lines (3) 3
chimeric-antigen-receptor (3) 3
cik (3) 3
clinical trials as topic (3) 3
cord blood stem cell transplantation (3) 3
culture-initiating cells (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer, ISSN 1476-4598, 12/2009, Volume 8, Issue 1, pp. 118 - 118
Background: Osteosarcoma (OS) is the most common primary bone tumour in children and young adults. Despite improved prognosis, metastatic or relapsed OS... 
ACTIVATION | SOLID TUMORS | ONCOLOGY | BIOCHEMISTRY & MOLECULAR BIOLOGY | ENDOTHELIAL-CELLS | ITALIAN-SARCOMA-GROUP | MAP-KINASES | MUTATIONS | FACTOR RECEPTOR | EXPRESSION | CANCER | PROGRESSION | Niacinamide - analogs & derivatives | Osteosarcoma - drug therapy | Vascular Endothelial Growth Factor A - biosynthesis | Cytoskeletal Proteins - antagonists & inhibitors | Apoptosis - drug effects | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Extracellular Signal-Regulated MAP Kinases - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - metabolism | Benzenesulfonates - pharmacology | Neoplasm Metastasis - prevention & control | Osteosarcoma - blood supply | Cytoskeletal Proteins - metabolism | Female | Neovascularization, Pathologic - prevention & control | Antineoplastic Agents - pharmacology | Matrix Metalloproteinase 2 - biosynthesis | Osteosarcoma - metabolism | Pyridines - therapeutic use | Down-Regulation - drug effects | Cell Division - drug effects | Animals | Myeloid Cell Leukemia Sequence 1 Protein | Cell Line, Tumor | Matrix Metalloproteinase Inhibitors | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Pyridines - pharmacology | Osteosarcoma - pathology | Development and progression | Diagnosis | Drug therapy | Osteosarcoma | Risk factors | Studies | Proteins | Medical research | Kinases
Journal Article
Journal of Cellular Biochemistry, ISSN 0730-2312, 03/2006, Volume 97, Issue 4, pp. 744 - 754
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2277 - 2288
Purpose: The MHC-unrestricted activity of cytokine-induced killer (CIK) cells against chemo-surviving melanoma cancer stem cells (mCSC) was explored, as CSCs... 
METASTATIC MELANOMA | ONCOLOGY | LENTIVIRUS VECTOR | IN-VIVO | THERAPY RESISTANCE | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | HLA BARRIERS | CIK CELLS | ANTITUMOR-ACTIVITY | CD8(+) T-CELLS | Nitrosourea Compounds - administration & dosage | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Neoplastic Stem Cells - immunology | Lentivirus - genetics | Immunotherapy, Adoptive - methods | Carcinogenesis - immunology | Carcinogenesis - genetics | Neoplasm Recurrence, Local | Drug Resistance, Neoplasm - immunology | Melanoma - pathology | Neoplastic Stem Cells - transplantation | Cytokine-Induced Killer Cells - immunology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cytokine-Induced Killer Cells - transplantation | Cell Line, Tumor | Mice | Organophosphorus Compounds - administration & dosage | Melanoma - therapy | Cytotoxicity, Immunologic | Autografts | Animal models | Cytokines | Oct-4 protein | Immunodeficiency | Melanoma | Chemoresistance | Stem cell transplantation | Gene expression | Anticancer properties | Infusion | Design engineering | Killer cells | Chemotherapy | Dilution | Major histocompatibility complex | Allografts | Experimental design | Immunotherapy | Stem cells | Lysis | Xenografts | Antitumor activity | Cancer
Journal Article
Molecular Cancer, ISSN 1476-4598, 04/2017, Volume 16, Issue 1, pp. 86 - 15
Background: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an... 
PARP1 inhibitors | DNA-damaging agents | Bone and soft tissue sarcomas | Predictive biomarkers | Olaparib | Trabectedin | Drug synergism | POLY(ADP-RIBOSE) POLYMERASE | DNA-DAMAGE RESPONSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | OLAPARIB MAINTENANCE THERAPY | EWING SARCOMA | BREAST-CANCER | ONCOLOGY | ADP-RIBOSE POLYMERASE | HOMOLOGOUS RECOMBINATION | VELIPARIB ABT-888 | REFRACTORY SOLID TUMORS | PHASE-I | DNA Damage - drug effects | Piperazines - administration & dosage | Phthalazines - administration & dosage | Apoptosis - drug effects | Humans | Tetrahydroisoquinolines - administration & dosage | Sarcoma - drug therapy | Sarcoma - pathology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Comparative Genomic Hybridization | Dioxoles - administration & dosage | Cell Line, Tumor | Biomarkers, Tumor - genetics | Mice | Gene Expression Regulation, Neoplastic - drug effects | Sarcoma - genetics | Poly (ADP-Ribose) Polymerase-1 - genetics | Drugs | Biotechnology | Animal models | Profiling | DNA damage | Lung cancer | Hybridization | Kinases | DNA repair | Synergism | Alkylation | Anticancer properties | Biomedical materials | Pathways | Osteosarcoma | Rodents | Xenografts | Cell cycle | Biocompatibility | Bioindicators | Damage | Deoxyribonucleic acid--DNA | Enzymes | Sarcoma | Tumor cells | Breast cancer | Gene expression | Polymerase chain reaction | Poly(ADP-ribose) Polymerase 1 | Chemotherapy | Inhibitors | Cell death | Cell lines | Biomarkers | Antitumor activity | In vitro methods and tests | Apoptosis
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 3591 - 3591
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2013, Volume 19, Issue 8, pp. 2117 - 2131
Purpose: The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma. However, in sorafenib-treated patients with... 
RAD001 EVEROLIMUS | MAMMALIAN TARGET | RAPAMYCIN | ANGIOGENESIS | ONCOLOGY | PATHWAY | ENDOTHELIAL-CELLS | PHASE-II | KINASE INHIBITORS | TUMOR VASCULATURE | CHILDRENS ONCOLOGY GROUP | Immunohistochemistry | Niacinamide - analogs & derivatives | Osteosarcoma - drug therapy | AMP-Activated Protein Kinases - metabolism | Reactive Oxygen Species - metabolism | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Mechanistic Target of Rapamycin Complex 2 | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - metabolism | Flow Cytometry | RNA Interference | Osteosarcoma - blood supply | Female | Neovascularization, Pathologic - prevention & control | Everolimus | Cell Survival - drug effects | Sirolimus - analogs & derivatives | Mice, SCID | Chick Embryo | Sirolimus - pharmacology | Blotting, Western | Niacinamide - administration & dosage | Up-Regulation - drug effects | Xenograft Model Antitumor Assays | Sirolimus - administration & dosage | Animals | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Inbred NOD | Mice | Neovascularization, Pathologic - metabolism | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Cell Cycle - drug effects | AMP-Activated Protein Kinases - genetics | Osteosarcoma - pathology
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2011, Volume 130, Issue 1, pp. 29 - 40
Trastuzumab has changed the prognosis of HER2 positive breast cancers. Despite this progress, resistance to trastuzumab occurs in most patients. Newer... 
Resistance | Mcl-1 | Medicine & Public Health | Sorafenib | Oncology | Breast cancer | Lapatinib | Survivin | HER2 | Trastuzumab | ADJUVANT CHEMOTHERAPY | APOPTOSIS | ACTIVATION | DOWN-REGULATION | COMBINATION | DOCETAXEL | ONCOLOGY | HERCEPTIN | ERBB2 | CONTRIBUTES | EXPRESSION | Niacinamide - analogs & derivatives | Receptor, ErbB-2 - genetics | Inhibitor of Apoptosis Proteins - genetics | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Phosphatidylinositol 3-Kinases - metabolism | Breast Neoplasms - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Benzenesulfonates - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Antineoplastic Agents - pharmacology | Inhibitor of Apoptosis Proteins - metabolism | Receptor, ErbB-2 - antagonists & inhibitors | Gene Expression Regulation, Neoplastic - drug effects | Oncogene Protein v-akt - metabolism | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Mice, SCID | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Signal Transduction - drug effects | Tumor Burden - drug effects | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Myeloid Cell Leukemia Sequence 1 Protein | Cell Line, Tumor | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | RNA, Small Interfering | Quinazolines - pharmacology | Proto-Oncogene Proteins c-bcl-2 - genetics | Mitogen-Activated Protein Kinases - metabolism | Proteins | Prognosis
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2014, Volume 14, Issue 1, pp. 918 - 918
Journal Article